The findings that p53 interacts with Rb, PTEN and AR in advanced prostate cancer, and synergizes with Rb in the development of prostate cancer, have important implications for the treatment of advanced prostate cancer, and that exploring gene interactions and combining therapies may be of immense help in addressing drug resistance in advanced prostate cancer. This evidence concerns the gene AR and prostate cancer.